Shares of Immune Design Corp (NASDAQ:IMDZ) dropped 2.9% on Thursday . The company traded as low as $3.30 and last traded at $3.30. Approximately 316,017 shares traded hands during trading, a decline of 48% from the average daily volume of 612,087 shares. The stock had previously closed at $3.40.

IMDZ has been the subject of a number of recent analyst reports. Wells Fargo & Co downgraded Immune Design from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $29.00 to $10.00 in a report on Tuesday, October 17th. ValuEngine downgraded Immune Design from a “sell” rating to a “strong sell” rating in a report on Saturday, October 21st. Cowen reiterated a “buy” rating on shares of Immune Design in a report on Monday, December 11th. Finally, Zacks Investment Research upgraded Immune Design from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a report on Monday, November 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $13.06.

The firm has a market capitalization of $156.19, a PE ratio of -1.53 and a beta of 2.36.

Immune Design (NASDAQ:IMDZ) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.11. The company had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $0.62 million. Immune Design had a negative net margin of 619.62% and a negative return on equity of 68.69%. equities analysts expect that Immune Design Corp will post -1.89 earnings per share for the current fiscal year.

In related news, major shareholder Leo Guthart acquired 20,000 shares of the business’s stock in a transaction dated Monday, January 8th. The shares were bought at an average price of $3.90 per share, with a total value of $78,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Carlos V. Paya sold 7,970 shares of the stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $4.17, for a total transaction of $33,234.90. Following the transaction, the chief executive officer now directly owns 114,560 shares in the company, valued at approximately $477,715.20. The disclosure for this sale can be found here. Insiders have sold a total of 13,959 shares of company stock worth $58,209 in the last three months. Insiders own 20.70% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Victory Capital Management Inc. boosted its position in shares of Immune Design by 4.2% during the 3rd quarter. Victory Capital Management Inc. now owns 2,060,234 shares of the biotechnology company’s stock worth $21,324,000 after purchasing an additional 82,670 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Immune Design by 118.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 530,702 shares of the biotechnology company’s stock worth $5,175,000 after purchasing an additional 288,009 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Immune Design by 37.9% during the 2nd quarter. Vanguard Group Inc. now owns 524,999 shares of the biotechnology company’s stock worth $5,118,000 after purchasing an additional 144,408 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Immune Design by 46.9% during the 2nd quarter. Wells Fargo & Company MN now owns 218,700 shares of the biotechnology company’s stock worth $2,132,000 after purchasing an additional 69,813 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of Immune Design by 32.8% during the 2nd quarter. Northern Trust Corp now owns 180,877 shares of the biotechnology company’s stock worth $1,764,000 after purchasing an additional 44,653 shares in the last quarter. 29.38% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was first reported by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.watchlistnews.com/immune-design-imdz-shares-down-2-9/1837765.html.

About Immune Design

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.